Optimized TMS for Depression

(TARGET Trial)

Recruiting at 1 trial location

Overseen By Jade T Truong, BS

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Stanford University

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

145 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for Enhancing TEPs (TARGET).

Who Is on the Research Team?

Corey J Keller, MD, PhD

Principal Investigator

Stanford University

Are You a Good Fit for This Trial?

This trial is for individuals with Major Depressive Disorder who have not responded well to standard treatments. Participants must be eligible for brain imaging and TMS procedures, but cannot join if they have metal implants in their head, seizure disorders, or are currently pregnant.

Inclusion Criteria

In a current depressive episode, assessed through a Structured Clinical Interview for DSM-5 (SCID-5)

Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales

I have moderate-to-severe depression based on my QIDS score.

Exclusion Criteria

Those with a contraindication for MRIs (e.g. implanted metal)

Any unstable medical condition

Active substance abuse

What Are the Treatments Tested in This Trial?

Interventions

• TARGET

Trial Overview The study tests different types of Transcranial Magnetic Stimulation (TMS) therapy: non-optimized vs TARGET-optimized TMS. It also uses EEG and iEEG recordings to measure brain activity and aims to find better ways to treat depression by adjusting brain excitability.

How Is the Trial Designed?

Group I: Sham TMS, Active TMS with iEEG Experimental Treatment 3 Interventions

Neurosurgical participants receive sham single-pulse TMS followed by active single-pulse TMS at predefined dlPFC sites during intracranial EEG recording. The order of stimulation conditions is randomized.

Group II: Optimized TMS, Non-optimized TMS with EEG Experimental Treatment 3 Interventions

Participants receive both TARGET optimized single-pulse TMS and non-optimized (open-loop) single-pulse TMS to the dlPFC while undergoing concurrent scalp EEG. The sequence of optimized and non-optimized stimulation is randomized.

Group III: Non-optimized TMS, Optimized TMS with EEG Experimental Treatment 3 Interventions

Participants receive non-optimized (open-loop) single-pulse TMS followed by TARGET optimized single-pulse TMS to the dlPFC with concurrent scalp EEG. The order of stimulation conditions is randomized.

Group IV: Active TMS, Sham TMS with iEEG Experimental Treatment 3 Interventions

Neurosurgical participants receive both active single-pulse TMS and sham single-pulse TMS delivered to predefined dlPFC sites while undergoing intracranial EEG recording. The order of active and sham stimulation is randomized.

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+